Prothena Corp Public (PRTA) Share-based Compensation (2012 - 2026)
Prothena Corp Public (PRTA) recorded quarterly Share-based Compensation of $6.9 million in Q1 2026, down 2.25% quarter-over-quarter from $7.1 million in Q4 2025, and down 36.84% on a YoY basis from $10.9 million in Q1 2025.
Prothena Corp Public (PRTA) Share-based Compensation (2012 - 2026) Analysis & Trends
Prothena Corp Public's Share-based Compensation history runs 15 years deep, the most recent figure standing at $6.9 million for Q1 2026.
- In Q1 2026, Share-based Compensation fell 36.84% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $33.6 million (down 24.53% YoY), while the FY2025 annual figure was $37.6 million, down 18.11% from the prior year.
- Share-based Compensation was $6.9 million for Q1 2026 at Prothena Corp Public, down from $7.1 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $12.4 million in Q2 2025 to a low of $6.9 million in Q1 2026.
- Historically, Share-based Compensation has averaged $9.6 million across 5 years, with a median of $10.1 million in 2023.
- The sharpest annual moves came in 2023 and 2026: Share-based Compensation surged 49.06% in 2023, then tumbled 36.84% in 2026.
- A 5-year view of Share-based Compensation shows it stood at $7.4 million in 2022, then soared by 49.06% to $11.1 million in 2023, then decreased by 5.05% to $10.5 million in 2024, then plunged by 32.76% to $7.1 million in 2025, then fell by 2.25% to $6.9 million in 2026.
- The last three Share-based Compensation figures came in at $6.9 million (Q1 2026), $7.1 million (Q4 2025), and $7.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Prothena Corp Public | 479.08 Mn | 149.61 Mn | - | 6.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.92 Mn |
| Mar 31, 2026 | 6.92 Mn |
| Dec 31, 2025 | 7.07 Mn |
| Dec 31, 2025 | 7.07 Mn |
| Sep 30, 2025 | 7.20 Mn |
| Sep 30, 2025 | 7.20 Mn |
| Jun 30, 2025 | 12.42 Mn |
| Jun 30, 2025 | 12.42 Mn |
| Mar 31, 2025 | 10.95 Mn |
| Mar 31, 2025 | 10.95 Mn |
| Dec 31, 2024 | 10.52 Mn |
| Dec 31, 2024 | 10.52 Mn |
| Sep 30, 2024 | 11.02 Mn |
| Sep 30, 2024 | 11.02 Mn |
| Jun 30, 2024 | 12.04 Mn |
| Jun 30, 2024 | 12.04 Mn |
| Mar 31, 2024 | 12.38 Mn |
| Mar 31, 2024 | 12.38 Mn |
| Dec 31, 2023 | 11.08 Mn |
| Dec 31, 2023 | 11.08 Mn |